ロード中...
Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
Gemtuzumab ozogamicin (GO), a humanized anti-CD33 monoclonal antibody conjugated to the cytotoxic antibiotic agent calicheamicin, is approved for the treatment of newly-diagnosed CD33 + AML in adults and children ≥ 1 month old, and relapsed or refractory CD33 + AML in adults and children ≥ 2 years o...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7559451/ https://ncbi.nlm.nih.gov/pubmed/33059764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-00975-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|